Gdansk

• Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended recruitment
  2024-511096-15-00 5 2014-08-01 Breast Cancer
• A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study Ended recruitment
  2023-503803-27-00 5 2013-10-25 B-cell non-Hodgkin's lymphoma and cGVHD
• Phase 2a study to assess the efficacy and safety of GIA632 in adult participants with moderate to severe atopic dermatitis Halted
  2025-521503-43-00 4 2026-02-12 Atopic dermatitis
• A 24-week with possible extension, prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel group with a randomiza … Halted
  2024-514538-19-00 5 2025-11-26 Mastocytosis
• Corticotrophin Releasing Factor 2 Agonist For the Treatment of Worsening Heart Failure (WHF) – The CRAFT-WHF Study Halted
  2024-518951-52-00 4 2025-11-12 Worsening Heart Failure
• A Phase 3 Study of NTLA 2001 in participants with amyloidosis with cardiac muscle disease. Halted
  2023-507220-23-00 5 2024-07-26 Transthyretin Amyloidosis with Cardiomyopathy
• A Phase 3 Trial to Evaluate the Efficacy, Safety, and Tolerability of Zasocitinib Compared to Deucravacitinib in Participants With Moderate- … Ended
  2024-512497-10-00 5 2025-09-16 Moderate to Severe Plaque Psoriasis
• Phase 2b Randomized, Double-Blind Study with Phage for CF Subjects with Pseudomonas Lung Infection Ended
  2024-519856-94-00 4 2025-08-18 Cystic fibrosis
• Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy Ended
  2024-513435-24-01 4 2025-06-03 Neuropathic Pain; Distal Sensory Polyneuropathy
• A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of … Ended
  2024-517814-13-00 4 2025-04-30 Moderate to Severe Atopic Dermatitis
• A trial to learn how safe AZD0022 is, how well it works, and how it moves throughout the body over time in adults with tumors that have a KR … Ended
  2024-516699-14-00 7 2025-04-23 Non Small Cell Lung Cancer Colorectal Cancer Pancreatic Ductal Adenoca
• A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity Ended
  2024-513679-42-00 4 2025-04-09 Obesity
• Open-label basket study for safety and pharmacokinetics evaluation of INF904 in subjects with CSU or HS Ended
  2024-515615-22-00 4 2025-04-02 Moderate to Severe Chronic Spontaneous Urticaria (CSU) or Moderate to
• A Study of Eciskafusp Alfa and Bacillus Calmette-Guérin (BCG) in Participants with High-Risk Bladder Cancer Unresponsive to BCG Treatment Ended
  2024-515410-41-00 9 2025-04-01 BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC)
• Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated Ended
  2024-512505-66-00 10 2025-03-03 HIV-1 Infection
• Impact of trimetazidine on endothelial function and biomarkers correlating with the prognosis of heart failure with preserved ejection fract … Ended
  2023-506138-65-00 6 2025-02-20 Heart failure with preserved ejection fraction
• A Phase 2, Dose-Ranging Study of LY4100511 (DC-853) in Adult Participants with Moderate-to-Severe Plaque Psoriasis Ended
  2024-512207-39-00 4 2025-01-30 Plaque Psoriasis
• Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study of Efficacy and Safety of ESK-001 for Moderate to Severe Pl … Ended
  2023-507193-40-00 5 2025-01-16 Moderate to Severe Plaque Psoriasis
• A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy a … Ended
  2024-513104-34-00 4 2024-11-25 Major Depressive Disorder
• Study of Levosimendan Therapy in low ejection fraction Takotsubo Syndrome Ended
  2024-515060-32-00 5 2024-11-22 Takotsubo syndrome
• A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as … Ended
  2024-511557-21-00 5 2024-11-14 Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia
• A study to investigate behavioral and other co-occurring outcomes with Epid(i/y)olex as add-on therapy in participants aged 1 to 65 years of … Ended
  2023-507426-17-00 11 2024-11-12 Tuberous Scerlosis Complex
• Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures – SHIN … Ended
  2023-508812-45-00 10 2024-11-11 Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures
• Lowering of LDL-C with rosuvastatin or single-pill combination rosuvastatin/ezetimibe in high/very high-risk patients with hyperlipidaemia – … Ended
  2023-504914-31-00 11 2024-11-10 Hyperlipidaemia

Showing 649–672 of 854 trials